Fri, Nov 21, 2014, 7:21 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Orion Marine Group, Inc Message Board

rchites 951 posts  |  Last Activity: 3 hours ago Member since: Apr 12, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    monoclonal antibodies

    by rchites Nov 3, 2014 7:52 PM
    rchites rchites Nov 3, 2014 8:27 PM Flag

    This is nothing new for ROBERT ERWIN who was Chairman of ICON. He has been though the ropes and knows the pipeline and manufacturing partners. MELISSA Didn't. She is the one that mis-spoke and lied. FUTURE PROOFING _ Introduction With monoclonal antibody products now the dominant component of the biopharmaceutical market and continued interest in this exciting class of products driving overall sales of biopharmaceutical products in the future … ZMAPP – overlooked a major step- One of the greatest challenges facing biopharmaceutical companies is ensuring adequate manufacturing capacity for products that are under development and potentially years away from commercialization. Companies that don’t have manufacturing facilities and capacity must secure manufacturing capability, acquiring existing manufacturing facilities, outsourcing production to a contract manufacturing organization (CMO), or merge. ICON/Kentucky Mapp is no where with out facilities (CMO) and patents - get it Melissa!!!!!!!!!!!!!!!

  • Reply to

    monoclonal antibodies

    by rchites Nov 3, 2014 7:52 PM
    rchites rchites Nov 3, 2014 8:16 PM Flag

    Check out $$$$$$$$$monoclonal antibodies $$$$$$$$$$$$ The GreenVax plant will be licensed by iBio Inc. On the Texas A& M complex. The company will provide the iBioLaunch technology platform and provide technology transfer services to G-Con to be implemented in the Bryan facility. The facility will initially produce H1N1 vaccines but the technology from iBio also supports other flu strains, cancer and infectious diseases. In February 2010, the GreenVax project received $40m funding from the Defense Advanced Research Projects Agency (DARPA) of the US Department of Defense. The public-private-partnership is largely financed by DARPA. The GreenVax project is expected to generate about 4,000 jobs and inject $800m into the state's economy by its 10th year of operation, according to The Perryman Group. Apart from vaccines, the plant is also expected to produce other biologics such as monoclonal antibodies for cancer therapy. This was funded by DARPA for defense reasons also......... EVEN EBOLA - Melissa !!!!!!!!!!!!!

  • Check out MAPP JAZZ and IBIO................ The markets are huge for these therapies.......... Melissa didn't address this little OMISSION .......... This was her wrong action , ignorance or just attributable to bad judgment .......... WAS it intentional ADAM and Melissa#$%$ pieces yes... "; "she was quick to point out Robert financial decisions and leaves out the most important parts of the company........ errors"; "I could understand but blatant false statement of KNOWN facts is criminal. SEARCH monoclonal antibodies for possible use of IBIOs PLATFORM with NOVICIs' grammr. They can copy animal cells and replace the drugs with plantibodies. This is the area Robert steered the company.......... YES it can be used in EBOLA. YES IBIO has many patents in this field. YES, GATES is here because of this. Why he was interested in the companies technology. GE plants going around the world will have this platform........... BRAZIL will make cheap drugs. Some of the world big selling drugs could be made cheaper...... I can post the patents , drugs and technology of duplication but is might get boring. The key is the huge MARKET overlooked by a few million shares. (((((((((((((((((((((((((((((((((((((((((((((((((((( sic ))))))))))))))))))))))))))))))))))))))))))))))))))

  • Reply to

    IBIO Lawsuit

    by johnflynch1 Nov 2, 2014 8:03 PM
    rchites rchites Nov 3, 2014 7:18 PM Flag

    I haven't lost a dime and have got in cheaper now. People lost money as they panicked. Who wouldn't with that hit piece #$%$. Melissa lied and exaggerated the whole mess. From the financing lies about selling at .44 to no pipeline, or technology having no role in ebola. Even the not listing Ebola on the financial statements a a very elementary , illogical slam. The platform and creation of the antibodies can defiantly be applied to EBOLA. If she is to stupid to see the connections of the player , Novicci and Robert past with ICON she is an idiot. That isn't Roberts fault she has no investigative talents for truth and facts. The suits are going no where and the stock could be at 5 in a couple weeks. It was just a chance to add cheap. The stock was at .8 before the Ebola run. It was at .9 earlier this week. Now people are sorting fact from fiction and Melissa is looking like $%^&*()_. I don't see where Robert went wrong. The financing had to happen in August. The limited sales along the way is at the PPS of the time period. LIKE 500,000 of the 10 million was at .44. YES . The stock has traded 11 million average for a period. ONE DAY 60 million traded between 2 and 3 dollars. I hope he got rid of a few that day. ADAM and Melissa had silly pieces only looking at a small piece of the company and not understanding the platform at all. IF they understood plantibodies they would see the platform could be used for many different diseases. JAZZ has some of the same interest as IBIO. OURS is just with plant antibodies. Which has many advantages. JAZZ would be a good suitor. SO would MAPP or ICON............ They all have good reason to invest or buy us. IF you think you have a good argument for IBIO wrong doing I would like to see it. Melissa just looks like a delusional ghost writer for a #$%$, convict and slime buckets. they made a lot of money of many of us and will make more on the call options ................ YES go long .

  • Reply to

    TECHNOLOGY MATTERS .... IBIO. $7 NEXT WEEK

    by ambo_988 Oct 17, 2014 5:52 PM
    rchites rchites Nov 3, 2014 6:57 PM Flag

    The one with the most to lose is ICON/BAYER. They could lose the USA sales all together. Would that be incentive for them to buy IBIO ? Maybe? The team Now is Texas A & M / Caliber/IBIO.... The team that cant ramp is Bayer/ICON/Kentucky BIO .... ZMapp wants Animal from Amgen and the BARDA team will decide on a Plant ZMapp after NOV 10th. GSK works with Texas A&M. Plantibodies research has been patented by ICON in Europe and IBIO in the USA. Big pharma might just jump on IBIO as ZMapp is bringing them into the news and a different light. JAZZ has the Monoclonal antibody therapies.... It is a form of immunotherapy that uses monoclonal antibodies (mAb) to specifically bind to target cells or proteins. This may then stimulate the patient's immune system to attack those cells. It is possible to create a mAb specific to almost any extracellular/ cell surface target, and thus there is a large amount of research and development currently being undertaken to create monoclonals for numerous serious diseases (such as rheumatoid arthritis, multiple sclerosis, Alzheimer's disease, Ebola[1] and different types of cancers). I see somebody say IBIO is a JAZZ........................... He may be right enough for them to take us out for the plantibodies................ It could be very rewarding to get them cheap and fast.............. Some body is going to jump.................... on this................... could you see them curing Alzheimer's with JAZZ?

  • Reply to

    TECHNOLOGY MATTERS .... IBIO. $7 NEXT WEEK

    by ambo_988 Oct 17, 2014 5:52 PM
    rchites rchites Nov 3, 2014 5:55 PM Flag

    I am betting on a take out around 5 dollars from PFE, GSK or Amgen. They all past up plant antibodies years ago. With new advancements its looking promising again. They may find IBIO has the USA locked up with patents and see this is the best entry. Amgen is having problems and must over come some obstacles with animal ZMapp. GSK is tied in with Texas A&M. Rumors have been going around with PFE.

  • Reply to

    IBIO Lawsuit

    by johnflynch1 Nov 2, 2014 8:03 PM
    rchites rchites Nov 3, 2014 5:48 PM Flag

    I doubled down two times .

  • rchites rchites Nov 3, 2014 5:47 PM Flag

    ROBERT ERWINS Profile is very nice also. He was there in the beginning with ICON and helped built it up to the acquisition. He is CEO here and Chairman at NOVICI. We have strong management despite what has been said. They know financing better then most. They are on top of what is going on and the shorts will be rocket fuel soon.

  • rchites rchites Nov 3, 2014 5:31 PM Flag

    VAPE , CBIS and TRTC was moving today. THE MJ stocks have been going up for a month now. It looks like they are all picking up speed. This one has done the best by far. I am Happy,

  • rchites rchites Nov 3, 2014 12:43 PM Flag

    GE across the globe. Gates will fund many diseases vaccines. ITS what he does now. The hunter crew is done here as the charts suggest. They will be making money on the way up with me. .

  • rchites rchites Nov 3, 2014 12:40 PM Flag

    I averaged down like many people here. Its not unusual to run into crooked short selling after lies and a hit piece. Most of us have losses right here. IN two weeks the story will be much different. JUST LIKE today the shorts hit the stock and its climbing back. It will rocket soon enough. YOU cant stop Ebola and cures.

  • rchites rchites Nov 3, 2014 11:08 AM Flag

    the Purchase Agreement with Aspire Capital as a source of funding will depend on a number of factors, including the prevailing market price of our common stock, the volume of trading in our common stock and the extent to which we are able to secure(((( funds from other sources.)))) The number of shares that we may sell to Aspire Capital under the Purchase Agreement on any given day and during the term of the agreement is limited. Minimum of .44 cents.......... That would be nice to see they didn't sell many. I am betting they sold a few above 1 & 2 dollars. BIOTECHNOLOGY has been hot for a couple years. With major press and contracts this could do very well. Caliber , Gates, and GE are going to make this collected by funds.

  • rchites rchites Nov 3, 2014 10:53 AM Flag

    RON Both told me it was over time also. I checked the earnings report it said the same. That was back in August any way. I bet they have made a lot of money lately. The best part is the platform is doing well building an infrastructure

  • RIGHT before shorts cover....... before the Barda confirmation .... this PPS is cheap for the huge spending in the industry on drugs. IBIO and ICON have a lock on this technology and the big boys will want in. EVERYBODY needs to increase their pipeline. Its only a few weeks away from sky rocketing with news ............... BARDA will produce some plant drugs....... ...... This is the greatest time a person could buy. AFTER the platform is complete and world demand.

  • rchites by rchites Nov 3, 2014 9:39 AM Flag

    This august offering didn't happen at one rate of PPS... Over time and they could have had a huge wind fall lately. rhmystic don't see the great platform , Gates, infrastructure , GE across the globe and BRAZIL , china news. The platform is growing and we should be getting a huge deal or ICON license shortly. IBIO was created for what is happening with plantibodies and their hard work and cash is paying off....... ITS PAYING OFF ............... the stock is very undervalued and a take out candidate.

  • rchites rchites Nov 3, 2014 9:26 AM Flag

    1) stock manipulation gets SEC attention. 2) Gates news working with disease, malaria and expanding to other diseases 3) Mapp and Novici contract 4) Takover and bidding war PFE rumors, GSK working with Texas A & M /caliber/IBIO 5 ) GE expands network 6) Testing of Zmapp 6) Hunter and Melissa share a cell 7) ICON partnership 8) ICON uses Fraunhofer with our license double royalties from Fraunhofer and ICON , platform goes bulistic 9) Major pharmaceutical announce license GSK, PFE, Amgen, Bayer. 10) Major outbreak NY 11 GRAMMR /ibiolaunch solve Mapps ramping problems 12) North Carolina NOVN contract 13) stockpile contract 14) Sierra Leone’s health worker mortality is 71 percent, Liberia’s is 51 percent and Guinea’s is 52 percent, reported TIME on Oct. 3. In Liberia, health workers are under such duress and being paid so little money that they staged a two-day strike for higher danger wages this week.

  • rchites rchites Nov 3, 2014 8:52 AM Flag

    Its clear the financing was for 20 million shares ..... IBIO trades on average lately of 11 million a day. ONE day they traded 60 million shares. The offering is sold over time unlike what Allen stated and since august it has been priced in. These crooks are delusional but effective. They will be placing the call options soon. Times running out for them.

  • Reply to

    My SA blog on IBIO

    by jbad5 Nov 2, 2014 11:30 PM
    rchites rchites Nov 3, 2014 8:45 AM Flag

    Its obvious Kentucky is not big enough . Its also clear all ICON patents are in Europe and IBIO in the USA. when I looked at the patents I saw ICON has many more. They both talked of finding vectors , like expression, information to the cells and extraction of the desired antibodies produced from introduction of disease. IBIO talked about optimizing more. Robert could have led the science in that direction with the platform. Duplicating fast, cloning and with precision is what it is about. Roberts Chairmanship of NOVICI and Mapp talking to them should be a big red flag to shorts. ZMAPP needs more then ICON.

  • Reply to

    My SA blog on IBIO

    by jbad5 Nov 2, 2014 11:30 PM
    rchites rchites Nov 3, 2014 8:36 AM Flag

    They have been know to place call options at the end of the short. They make money both ways. Melissa is known for that. It happens soon. It would not surprise me to see this shoot 30 or 40 cents today.

  • Reply to

    end of short thesis

    by bababara00 Nov 3, 2014 4:47 AM
    rchites rchites Nov 3, 2014 8:33 AM Flag

    That was a very nice run down -------

ORN
11.33-0.06(-0.53%)Nov 21 4:02 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Foot Locker, Inc.
NYSEFri, Nov 21, 2014 4:00 PM EST
Aruba Networks, Inc.
NasdaqGSFri, Nov 21, 2014 4:00 PM EST